Trial Profile
A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Acronyms Hubble zoom
- Sponsors Takeda
- 28 Apr 2023 Planned End Date changed from 25 May 2025 to 24 Nov 2025.
- 28 Apr 2023 Planned primary completion date changed from 25 May 2025 to 26 May 2025.
- 06 Jan 2021 Planned End Date changed from 20 Dec 2024 to 25 May 2025.